A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Sitagliptin 100 mg Film-coated Tablets and Reference Product (JANUVIATM) in Healthy Thai Volunteers under Fasting Conditions
- Conditions
- Healthy Thai Volunteers
- Registration Number
- TCTR20200807004
- Lead Sponsor
- International Bio Service
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 26
1. Healthy Thai male or female subjects between the ages of 18 to 55 years.
2. Body mass index between 18.0 to 30.0 kg/m2.
3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening.
Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study.
4. Non-pregnant woman (negative pregnancy test) and not currently breast feeding.
5. Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to admission in Period 1. Injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to admission in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to admission in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to admission in Period 1:
- Postmenopausal for at least 1 year or
- Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months
6. Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after admission in Period 1 until 7 days after the end of study in Period 2.
7. Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
1.History serious hypersensitivity reactions, i.e., anaphylaxis, angioedema, exfoliative skin conditions including Stevens-Johnson syndrome, to sitagliptin, another dipeptidyl peptidase-4 (DPP-4) inhibitor or any other ingredient of the product
2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hypo-/hyperthyroid, diabetes), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hypo-/hypertension), psychiatric, neurologic (e.g. seizures), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness
3.History or evidence of type 1 diabetes mellitus, diabetic ketoacidosis
4.History or evidence of acute pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis
5.History or evidence of severe infection or serious accident within 14 days prior to check-in in each period
6.History or evidence of severe joint pain
7.History or evidence of bullous pemphigoid
8.History or evidence of heart failure
9.History or evidence of cardiovascular bleeding, gastrointestinal bleeding, gastric or duodenal or peptic ulcer
10.Have renal creatinine clearance (Clcr) <45 mL/min based on serum creatinine results, using glomerular filtration rate (GFR; Cockcroft-Gault formula), at the screening laboratory test
11.History of sensitivity to heparin or heparin-induced thrombocytopenia
12.Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19
13.History of problems with swallowing tablet or capsule
14.Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy
15.History of preceding diarrhea or dehydration within 24 hours prior to check-in in each period
16.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine)
17.12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject’s eligibility.
18.Investigation with blood sample shows positive test for HBsAg.
19.Investigation with blood sample shows fasting blood glucose level less than 70 mg/dl or more than 99 mg/dl at screening
20.Abnormal liver function, ≥ 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test
21.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in and continued for entire duration of the study
22.History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.)
23.History or evi
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug concentration in plasma 0-48 hr Pharmacokinetic evaluation
- Secondary Outcome Measures
Name Time Method Safety evaluation 0-48 hr Adverse events